NVO vs. NOVN.SW
Compare and contrast key facts about Novo Nordisk A/S (NVO) and Novartis AG (NOVN.SW).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NVO or NOVN.SW.
Correlation
The correlation between NVO and NOVN.SW is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NVO vs. NOVN.SW - Performance Comparison
Key characteristics
NVO:
-1.13
NOVN.SW:
0.22
NVO:
-1.60
NOVN.SW:
0.58
NVO:
0.79
NOVN.SW:
1.09
NVO:
-0.79
NOVN.SW:
0.43
NVO:
-1.49
NOVN.SW:
1.05
NVO:
31.49%
NOVN.SW:
6.89%
NVO:
42.36%
NOVN.SW:
19.88%
NVO:
-71.29%
NOVN.SW:
-42.25%
NVO:
-54.98%
NOVN.SW:
-8.69%
Fundamentals
NVO:
$306.30B
NOVN.SW:
CHF 186.07B
NVO:
$3.43
NOVN.SW:
CHF 5.27
NVO:
20.18
NOVN.SW:
17.88
NVO:
1.03
NOVN.SW:
1.36
NVO:
1.06
NOVN.SW:
3.50
NVO:
14.12
NOVN.SW:
5.87
NVO:
$225.05B
NOVN.SW:
CHF 53.22B
NVO:
$190.45B
NOVN.SW:
CHF 40.26B
NVO:
$113.24B
NOVN.SW:
CHF 16.05B
Returns By Period
In the year-to-date period, NVO achieves a -23.40% return, which is significantly lower than NOVN.SW's 6.39% return. Over the past 10 years, NVO has outperformed NOVN.SW with an annualized return of 10.95%, while NOVN.SW has yielded a comparatively lower 5.51% annualized return.
NVO
-23.40%
5.28%
-38.78%
-47.79%
17.60%
10.95%
NOVN.SW
6.39%
2.79%
1.47%
4.23%
7.25%
5.51%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NVO vs. NOVN.SW — Risk-Adjusted Performance Rank
NVO
NOVN.SW
NVO vs. NOVN.SW - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Novartis AG (NOVN.SW). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NVO vs. NOVN.SW - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 2.49%, less than NOVN.SW's 3.84% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 2.49% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
NOVN.SW Novartis AG | 3.84% | 3.72% | 3.77% | 3.91% | 3.94% | 3.72% | 3.27% | 3.98% | 3.98% | 4.35% | 3.58% | 3.17% |
Drawdowns
NVO vs. NOVN.SW - Drawdown Comparison
The maximum NVO drawdown since its inception was -71.29%, which is greater than NOVN.SW's maximum drawdown of -42.25%. Use the drawdown chart below to compare losses from any high point for NVO and NOVN.SW. For additional features, visit the drawdowns tool.
Volatility
NVO vs. NOVN.SW - Volatility Comparison
Novo Nordisk A/S (NVO) has a higher volatility of 17.28% compared to Novartis AG (NOVN.SW) at 11.85%. This indicates that NVO's price experiences larger fluctuations and is considered to be riskier than NOVN.SW based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NVO vs. NOVN.SW - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and Novartis AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVO vs. NOVN.SW - Profitability Comparison
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported a gross profit of 72.66B and revenue of 85.68B. Therefore, the gross margin over that period was 84.8%.
NOVN.SW - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Novartis AG reported a gross profit of 10.39B and revenue of 13.62B. Therefore, the gross margin over that period was 76.3%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported an operating income of 36.74B and revenue of 85.68B, resulting in an operating margin of 42.9%.
NOVN.SW - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Novartis AG reported an operating income of 4.66B and revenue of 13.62B, resulting in an operating margin of 34.2%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported a net income of 28.23B and revenue of 85.68B, resulting in a net margin of 33.0%.
NOVN.SW - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Novartis AG reported a net income of 3.61B and revenue of 13.62B, resulting in a net margin of 26.5%.